PMID- 27868366
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20171129
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 3
DP  - 2017 Mar
TI  - Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism 
      and endotoxemia after a high-fat meal in patients with type 2 diabetes.
PG  - 457-462
LID - 10.1111/dom.12831 [doi]
AB  - We aimed to investigate the effects of gemigliptin, a dipeptidyl peptidase-4 
      inhibitor, on postprandial lipoprotein levels and endotoxemia in a randomized, 
      double-blind, placebo-controlled, crossover study. Ten people with type 2 
      diabetes mellitus (T2DM), inadequately controlled with oral antidiabetic 
      medications and/or lifestyle modification, were randomized to gemigliptin or 
      placebo for 4 weeks. At the end of each treatment phase, the study participants 
      underwent a high-fat meal tolerance test and needle aspiration of abdominal 
      subcutaneous adipose tissue. The median (range) fasting and total area under the 
      curve of apolipoprotein B48 (ApoB48) were significantly lower with gemigliptin 
      than with placebo (2.9 [1.5-15.8] microg/mL vs 4.2 [1.3-23.4] microg/mL; P = .020; 35.3 
      [14.4-87.4] microg/mL x hour vs 42.2 [17.5-109.0] microg/mL x hour; P = .020, 
      respectively), whereas apolipoprotein B100 showed no significant difference. 
      Serum endotoxin levels were undetectable in 70% of the samples, so we were not 
      able to evaluate the effect of gemigliptin on endotoxemia. The gene expression of 
      inflammatory cytokines in subcutaneous adipose tissue was not affected by 
      gemigliptin. Gemigliptin reduced ApoB48 levels after a high-fat meal in 
      participants with T2DM. Whether systemic endotoxin levels can be reduced by 
      gemigliptin requires further investigation.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Ahn, Chang Ho
AU  - Ahn CH
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Kim, Eun Ky
AU  - Kim EK
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Min, Se Hee
AU  - Min SH
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Oh, Tae Jung
AU  - Oh TJ
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
FAU - Cho, Young Min
AU  - Cho YM
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20161219
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Adiponectin)
RN  - 0 (Apolipoprotein B-100)
RN  - 0 (Apolipoprotein B-48)
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Cytokines)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Endotoxins)
RN  - 0 (IL6 protein, human)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-6)
RN  - 0 (LC15-0444)
RN  - 0 (Piperidones)
RN  - 0 (Pyrimidines)
RN  - 0 (RNA, Messenger)
RN  - 0 (TNF protein, human)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9007-92-5 (Glucagon)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adiponectin/metabolism
MH  - Adult
MH  - Aged
MH  - Apolipoprotein B-100/metabolism
MH  - Apolipoprotein B-48/metabolism
MH  - Blood Glucose/metabolism
MH  - C-Reactive Protein/immunology
MH  - Cholesterol/metabolism
MH  - Cholesterol, HDL/metabolism
MH  - Cholesterol, LDL/metabolism
MH  - Cross-Over Studies
MH  - Cytokines/genetics/*immunology
MH  - Diabetes Mellitus, Type 2/*drug therapy/immunology/metabolism
MH  - Diet, High-Fat
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Endotoxemia
MH  - Endotoxins/blood
MH  - Female
MH  - Glucagon/metabolism
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Humans
MH  - Insulin/metabolism
MH  - Insulin Resistance
MH  - Interleukin-6/immunology
MH  - *Lipid Metabolism
MH  - Male
MH  - Middle Aged
MH  - Piperidones/*therapeutic use
MH  - Postprandial Period
MH  - Pyrimidines/*therapeutic use
MH  - RNA, Messenger/metabolism
MH  - Subcutaneous Fat, Abdominal/immunology/metabolism
MH  - Transcriptome
MH  - Triglycerides/metabolism
MH  - Tumor Necrosis Factor-alpha/immunology
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - antidiabetic drug
OT  - dyslipidaemia
OT  - randomized trial
EDAT- 2016/11/22 06:00
MHDA- 2017/11/08 06:00
CRDT- 2016/11/22 06:00
PHST- 2016/08/14 00:00 [received]
PHST- 2016/11/04 00:00 [revised]
PHST- 2016/11/15 00:00 [accepted]
PHST- 2016/11/22 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
PHST- 2016/11/22 06:00 [entrez]
AID - 10.1111/dom.12831 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 Mar;19(3):457-462. doi: 10.1111/dom.12831. Epub 2016 
      Dec 19.